摘要
目的探讨人血清中激肽释放酶（KLK）6的水平在上皮性卵巢癌诊断与随访中的价值。方法应用ELISA法检测30例上皮性卵巢癌、20例卵巢良性肿瘤患者和30例健康妇女外周血中KLK6的水平，同时使用化学发光法测定以上人员血清中CA125水平。并检测术后一周、3个月接受随访的12例上皮性卵巢癌患者血清中KLK6和CA125水平。结果术前上皮性卵巢癌患者血清中KLK6水平高于良性组和对照纽（P〈0．05）；KLK6水平与卵巢癌的临床分期、细胞分级、淋巴转移、复发／死亡有关（P〈0．05），与组织类型无关（P〉0．05）；上皮性卵巢癌患者术后KLK6与CA125水平显著低于术前（P〈0．05）。KLK6对上皮性卵巢癌诊断的敏感度为73．3％，特异度为85．0％，对Ⅰ—Ⅱ和Ⅲ—Ⅳ期卵巢癌诊断的敏感度分别为50．0％，88．9％。结论血清KLK6可作为上皮性卵巢癌实验室诊断、监测和预后的可靠指标之一。
Objective The aim of this study was to investigate the clinical value of human serum Kallikrein 6 for the diagnosis and monitor of pitheiial ovarian cancer. Methods Serum levels of KLK6 were analyzed with ELISA in 30 cases of epithelial ovarian carcinoma,20 cases of benign ovarian tumor and 30 cases of healthy women. In the meantime, serum CA125 was determined with chemiluminescence. Furthermore, serum levels of KLK6 and CA125 were also detected in 12 case of epithelial ovarian carcinoma with the same methods one week and the 3rd month postoperation of follow-up. Results Serum levels of KLK6 in epithelial ovarian carcinoma was higher than that in benign ovarian tumor and healthy women （ P 〈 0.05 ）. KLK6 also showed positive correlation with clinical stage, cytological grade, pelvic lymph node metastasis, recurrent or dead disease （ P 〈 0.05 ）. On the contrary, KLK6 showed no significant correlation with pathological types （ P 〉0.05）. After surgery of follow-up, KLK6 and CA125 were significantly decreased in 12 case of epithelial ovarian carcinoma （ P 〈0. 05 ）. Furthermore, the total sensitivity and specificity of KLK6 in the diagnosis of epithelial ovarian carcinoma was 73.3% and 85. 0% respectively, followed by the sensitivity to be 50.0% and 88.9% for the diagnosis of stage Ⅰ -Ⅱ and Ⅲ - Ⅳ disease. Conchmion Our resuits showed KLK6 may be one of the reliable indexes for the diagnosis and monitor of ovarian cancer.
出处
《中国医师杂志》
CAS
2009年第6期734-737,共4页
Journal of Chinese Physician
基金
基金项目：浙江省温州市科技局课题资助项目（Y20070023）
